N-(2-fluoro-benzyl)-N-indan-2-yl-2-(2-o-tolyl-piperidin-1-yl)-acetamide | 610298-33-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-(2-fluoro-benzyl)-N-indan-2-yl-2-(2-o-tolyl-piperidin-1-yl)-acetamide
• 英文别名: N-(2,3-dihydro-1H-inden-2-yl)-N-[(2-fluorophenyl)methyl]-2-[2-(2-methylphenyl)piperidin-1-yl]acetamide
• CAS: 610298-33-4
• 化学式: C₃₀H₃₃FN₂O
• 分子量: 456.603
• InChiKey: CYQMJPMALUKXDF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  34
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Substituted tetrahydroisoquinolines as C5a receptor modulators
  申请人：——

  公开号：US20040006069A1

  公开（公告）日：2004-01-08

  1 Substituted tetrahydroisoquinolines and related compounds are provided. Such compounds are ligands that may be used to modulate C5a receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological C5a receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

  提供了替代四氢异喹啉和相关化合物。这些化合物是配体，可用于调节体内或体外的C5a受体活性，并且在治疗与人类、驯化伴侣动物和家畜动物中的病理性C5a受体激活相关的疾病方面特别有用。提供了用于治疗此类疾病的药物组成物和使用它们的方法，以及用于受体定位研究的配体使用方法。
• Cyclic urea derivatives with 5-ht2c receptor activity
  申请人：Bromidge M Steven

  公开号：US20050154028A1

  公开（公告）日：2005-07-14

  Compounds of formula (I) or a pharmaceutically acceptable salt thereof, having 5HT 2C receptor activity, are disclosed: wherein a is 0,1,2,3,4 or 5; b is 1,2 or 3; Y is nitrogen or carbon; A is oxygen, nitrogen, —CONH—, —NHCO— or together with R 2 form a benzoxazolone group; R 1 is halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylthio, hydroxy, amino, mono- or di-C 1-6 alkylamino, nitro, CN, CF 3 , OCF 3 , aryl, arylC 1-6 alkyl, arylC 1-6 alkyloxy or arylC 1-6 alkylthio; R 2 is hydrogen, halogen, C 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkyl or haloC 1-6 alkoxy; R 3 is: (i) —NR 4 R 5 where R 4 and R 5 are independently hydrogen, C 1-6 alkyl or arylC 1-6 alkyl; or (ii) an optionally substituted N-linked heterocycle; or (iii) an optionally substituted C-linked heterocycle; ======= is a single bond or a double bond; and X is CH 2 or C═O (when ======= is a single bond) or X is CH (when ======= is a double bond). The preparation of these compounds and their use in therapy, especially for a CNS disorder such as depression or anxiety, are also disclosed.

  公开了式(I)化合物或其药学上可接受的盐，具有5HT2C受体活性：其中a为0、1、2、3、4或5；b为1、2或3；Y为氮或碳；A为氧、氮、-CONH-、-NHCO-或与R2一起形成苯并噁唑酮基团；R1为卤素、C1-6烷基、C1-6烷氧基、C1-6烷基硫基、羟基、氨基、单-或双C1-6烷基氨基、硝基、CN、CF3、O 、芳基、芳基C1-6烷基、芳基C1-6烷氧基或芳基C1-6烷硫基；R2为氢、卤素、C1-6烷基、C1-6烷氧基、卤代C1-6烷基或卤代C1-6烷氧基；R3为：（i）-NR4R5，其中R4和R5独立地为氢、C1-6烷基或芳基C1-6烷基；或（ii）可选地取代的N-连接杂环；或（iii）可选地取代的C-连接杂环；=======为单键或双键；X为CH2或C═O（当=======为单键时）或X为CH（当=======为双键时）。还公开了这些化合物的制备及其在治疗中的使用，特别是用于中枢神经系统障碍，如抑郁症或焦虑症。
• SUBSTITUTED TETRAHYDROISOQUINOLINES AS C5A RECEPTOR MODULATORS
  申请人：Neurogen Corporation

  公开号：EP1487798A1

  公开（公告）日：2004-12-22
• EP1487798A4
  申请人：——

  公开号：EP1487798A4

  公开（公告）日：2005-07-13
• US6777422B2
  申请人：——

  公开号：US6777422B2

  公开（公告）日：2004-08-17